APOB and metabolic dysfunction-associated steatohepatitis: The combined group of cirrhotic and noncirrhotic NASH patients still exhibited a significant 47% increase in plasma-apoB ASR from baseline to week 12 of ACCi therapy (30.4 ± 18.4 vs. 45.2 ± 15.4 mg/dl/day, P = 0.016, N = 16, Fig. 2G).